Comments on: Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

Comments on: Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint //dianhuaminglu.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4/ 创新疗法的发现、开发和商业化的生物制药公司�?/description> Thu, 04 May 2023 10:42:01 +0000 hourly 1 //wordpress.org/?v=6.6.2